Mini-Oral
Quizartinib
EHA 2025 | June 12-15, 2025
Hematology
The combination of an FLT3-ITD, NPM1mut, and an epigenetic regulatory gene mutation confers unique sensitivity to quizartinib: Analysis from the QuANTUM-First trial
Mark J. Levis